The FDA approved Nufymco as an interchangeable biosimilar to Lucentis, making it the second approved ranibizumab biosimilar ...
Combination therapy with a nonsteroidal mineralocorticoid receptor antagonist and an SGLT2 inhibitor reduced albuminuria more ...
Assessments used to calculate cardiovascular disease risk in the general population may not have the same predictive power ...
Self-reported knee crepitus may predict osteoarthritis 1 year following ACL reconstruction, according to findings published ...
ORLANDO — Children and adolescents with food allergy often experience substantial fear of negative social evaluation, ...
Calling eye drops “artificial tears” can mislead people into thinking the drops are more sophisticated than they truly are ...
Discontinuation of GLP-1 receptor agonists before pregnancy or early during pregnancy was tied to more gestational weight and ...
Autoantibody positivity rates were lower in people with dermatomyositis who used immunostimulatory herbs before disease onset ...
Among pediatric and adult patients with cystic fibrosis, the average number of chronic respiratory therapies used fell after ...
The question of whether invasive or noninvasive methods provide the best possible outcomes for patients with ...
AstraZeneca withdrew andexanet alfa, an antidote to several direct oral anticoagulants, from the U.S. market, ending U.S.
The FDA approved the first oral GLP-1 for lowering body weight according to a press release from Novo Nordisk. Oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback